These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15727728)

  • 1. The use of myeloperoxidase as a risk marker for atherosclerosis.
    Nambi V
    Curr Atheroscler Rep; 2005 Mar; 7(2):127-31. PubMed ID: 15727728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture.
    Teng N; Maghzal GJ; Talib J; Rashid I; Lau AK; Stocker R
    Redox Rep; 2017 Mar; 22(2):51-73. PubMed ID: 27884085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease.
    Haraguchi Y; Toh R; Hasokawa M; Nakajima H; Honjo T; Otsui K; Mori K; Miyamoto-Sasaki M; Shinohara M; Nishimura K; Ishida T; Hirata K
    Atherosclerosis; 2014 Jun; 234(2):288-94. PubMed ID: 24704632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between myeloperoxidase levels and risk of coronary artery disease.
    Zhang R; Brennan ML; Fu X; Aviles RJ; Pearce GL; Penn MS; Topol EJ; Sprecher DL; Hazen SL
    JAMA; 2001 Nov; 286(17):2136-42. PubMed ID: 11694155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease.
    Kubala L; Lu G; Baldus S; Berglund L; Eiserich JP
    Clin Chim Acta; 2008 Aug; 394(1-2):59-62. PubMed ID: 18440308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species.
    Pennathur S; Bergt C; Shao B; Byun J; Kassim SY; Singh P; Green PS; McDonald TO; Brunzell J; Chait A; Oram JF; O'brien K; Geary RL; Heinecke JW
    J Biol Chem; 2004 Oct; 279(41):42977-83. PubMed ID: 15292228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum.
    Schmitt D; Shen Z; Zhang R; Colles SM; Wu W; Salomon RG; Chen Y; Chisolm GM; Hazen SL
    Biochemistry; 1999 Dec; 38(51):16904-15. PubMed ID: 10606525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active and total myeloperoxidase in coronary artery disease and relation to clinical instability.
    Gach O; Brogneaux C; Franck T; Serteyn D; Legrand V; Pierard LA; Magne J
    Acta Cardiol; 2015 Oct; 70(5):522-7. PubMed ID: 26567811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocytes and neutrophils expressing myeloperoxidase occur in fibrous caps and thrombi in unstable coronary plaques.
    Tavora FR; Ripple M; Li L; Burke AP
    BMC Cardiovasc Disord; 2009 Jun; 9():27. PubMed ID: 19549340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liberation of vessel-adherent myeloperoxidase reflects plaque burden in patients with stable coronary artery disease.
    Rudolph TK; Schaper N; Klinke A; Demir C; Goldmann B; Lau D; Köster R; Hellmich M; Meinertz T; Baldus S; Rudolph V
    Atherosclerosis; 2013 Dec; 231(2):354-8. PubMed ID: 24267251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloperoxidase and coronary arterial disease: from research to clinical practice.
    Roman RM; Wendland AE; Polanczyk CA
    Arq Bras Cardiol; 2008 Jul; 91(1):e11-9. PubMed ID: 18660935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Coronary Endothelial Dysfunction Have Impaired Cholesterol Efflux Capacity and Reduced HDL Particle Concentration.
    Monette JS; Hutchins PM; Ronsein GE; Wimberger J; Irwin AD; Tang C; Sara JD; Shao B; Vaisar T; Lerman A; Heinecke JW
    Circ Res; 2016 Jun; 119(1):83-90. PubMed ID: 27114438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction.
    Goldmann BU; Rudolph V; Rudolph TK; Holle AK; Hillebrandt M; Meinertz T; Baldus S
    Free Radic Biol Med; 2009 Jul; 47(1):79-83. PubMed ID: 19362143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma myeloperoxidase is related to the severity of coronary artery disease.
    Düzgünçinar O; Yavuz B; Hazirolan T; Deniz A; Tokgözoğlu SL; Akata D; Demirpençe E
    Acta Cardiol; 2008 Apr; 63(2):147-52. PubMed ID: 18468192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating cardiovascular pathophysiology and anatomy in atherosclerosis.
    Stone PH
    Am Heart Hosp J; 2005; 3(3):187-92. PubMed ID: 16106140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome.
    Cavusoglu E; Ruwende C; Eng C; Chopra V; Yanamadala S; Clark LT; Pinsky DJ; Marmur JD
    Am J Cardiol; 2007 May; 99(10):1364-8. PubMed ID: 17493461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association between plasma myeloperoxidase levels and angiographic severity of coronary artery disease in patients with acute coronary syndrome.
    de Azevedo Lucio E; Gonçalves SC; Ribeiro JP; Nunes GL; de Oliveira JR; Araujo GN; Wainstein MV
    Inflamm Res; 2011 Feb; 60(2):137-42. PubMed ID: 20848159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
    Kimak E; Zięba B; Duma D; Solski J
    Lipids Health Dis; 2018 Apr; 17(1):71. PubMed ID: 29618370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease.
    Pawlus J; Hołub M; Kozuch M; Dabrowska M; Dobrzycki S
    Int J Lab Hematol; 2010 Jun; 32(3):320-8. PubMed ID: 20201999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease.
    Trentini A; Rosta V; Spadaro S; Bellini T; Rizzo P; Vieceli Dalla Sega F; Passaro A; Zuliani G; Gentili V; Campo G; Cervellati C
    Clin Chem Lab Med; 2020 Sep; 58(10):1749-1758. PubMed ID: 32031967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.